As shown in Fig. 1c and Supplementary Fig. 1c, the anti-lymphoma activity of CAR.CD19-T cells was superimposable to the control condition, in which emapalumab was not added to the co-culture, at all the ratios tested. This evidence concerns the gene CD19 and lymphoma.